Bimekizumab Efficacy in TNF-Refractory PsA Bimekizumab, a selective inhibitor of IL-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active PsA who previously failed therapy with TNFi inhibitors. https://t.co/NCJvhmisNe https://t.co/Tk2d7ILHl2

From 1055 new polyarthralgia presentations, 88 (8.3%) Dx w/ psoriatic arthritis. PsA Dx assoc w/ a +FamHx ( OR 4.14), psoriasis (OR=78.94), erosions (OR=5.74), US +power Doppler (OR=7.11). Neg assoc w/ +RF (OR 0.03), +CCP (OR 0.06). https://t.co/YXcqUq9JCi https://t.co/PLuU6cTDab

3388 pts in J Hopkins Scleroderma study found 29% w/ calcinosis (13.5% these w/ heavy burden calcinosis/HBC). Calcinosis assoc w/ diffuse SSc, disease severity (PH, ILD, CVD, GI, renal crisis, myopathy)(OR 2.9- 6.9) & PM/Scl Abs (OR 17.31) https://t.co/ksdPcH9W0O https://t.co/OvI9wytf5H

Oligoarticular PsA: FOREMOST Study Dr. Peter Nash discusses abstract 1018 at ACR22 Convergence. Abstract 1018: Characterization of Joint Distribution and Disease Burden in Patients with Early Oligoarticular PsA: Results from the Ongoing FOREMOST Study https://t.co/3vkUQnpm9F https://t.co/h5OijjETUk

Sensor-engineered glove evaluates hand function in RA Dr. David Liew discusses abstract 0904 at ACR22 Convergence. Abstract 0904: Testing the Hand Function with a Sensor-engineered Glove in Patients with Rheumatoid Arthritis https://t.co/e5VCOC56BC https://t.co/vfuVWMrqSj

Netherlands study of 220 consecutive inflammatory arthritis pts enrolled in electronic remote telehealth monitoring showed that 141 (64%) dropped out, with a median dropout at 17 wks ( moreso in women). Why? Simple is not alway simple... https://t.co/nziKil4vas https://t.co/oyyulMnIu1

National cohort of 20–39-yr old men - among ~1.3 million, 18,473 Dx w/ gout (incidence 3.36/1,000 PY). Developing metabolic syndr doubled #gout risk (aHR 2.31); MetS at all visits had 4x risk (aHR 3.82) & MetS recovery reduced gout risk by 59% https://t.co/bLmf1AL5VI https://t.co/8c47zk6vqu

Top 10 Pharma Revenues 2021: 1 J&J $93.77 billion (USD) 2 Pfizer $81.29 B 3 Roche $68.7 B 4 AbbVie S$56.2 B 5 Novartis $51.63 B 6 Merck $48.7 B 7 BMS $46.4 B 8 GSK $43.57 B 9. Sanofi $44.67 B 10. AstraZeneca $37.47 B https://t.co/ptFAyk4S5S https://t.co/cCtPboI53x

Goofy or Novel: "How gravity may cause irritable bowel syndrome". A hypothesis, published in the American Journal of Gastroenterology, describes how the intestines, spine, heart, nerves and brain evolved to manage gravity. https://t.co/lLyAkruyyy? https://t.co/TJH8Du8rm6

Was this a Mistake? HCQ Dose Reductions per AAOS Guidelines Following the 2016 American Academy of Ophthalmology Guidelines, rheums have dutifully reduced the dose of HCQ taken by patients with SLE to some number south of 5mg/kg per day. https://t.co/iToRttwPbC https://t.co/REpWkI7vC0

A Multidimensional Approach in the Management of Axial Spondylarthritis Abstract 1510 by Jones et al studied the effect of lifestyle on treatment response in patients with axial spondylarthritis. https://t.co/Y5syU5cX6Y https://t.co/PO7TZ3ZBOo

Visit our podcast channel and listen to experts from the #SLEEducatorsNetwork discuss how biologic therapies could help address key unmet needs in #lupus, and how clinicians can identify the most appropriate patients for biologics. #SponsoredbyGSKUSMA https://t.co/zYB48YvNDC https://t.co/gL67G5jQv8